Canagliflozin

Drug Profile

Canagliflozin

Alternative Names: Canaglu; Invokana; JNJ-28431754; TA-7284

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Developer Daiichi Sankyo Company; Johnson & Johnson; Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies
  • Phase II Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 28 Nov 2016 Kyoto Prefectural University of Medicine initiates enrolment in a clinical trial for Type-2 diabetes mellitus in Japan (UMIN000023044)
  • 23 Nov 2016 NICE recommends use of Canagliflozin as triple therapy for Type 2 diabetes mellitus (in combination with metformin and a sulfonylurea) in the UK
  • 12 Nov 2016 Pooled analysis of efficacy data from phase III trials in Type-2 diabetes mellitus presented at the 89th Annual Scientific Sessions of the American Heart Association (AHA-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top